| The library of integrated network-based cellular signatures NIH program: system-level cataloging of human cells response to perturbations AB Keenan, SL Jenkins, KM Jagodnik, S Koplev, E He, D Torre, Z Wang, ... Cell systems 6 (1), 13-24, 2018 | 390 | 2018 |
| A single-cell landscape of high-grade serous ovarian cancer B Izar, I Tirosh, EH Stover, I Wakiro, MS Cuoco, I Alter, C Rodman, ... Nature medicine 26 (8), 1271-1279, 2020 | 303 | 2020 |
| Multiomics profiling establishes the polypharmacology of FDA-approved CDK4/6 inhibitors and the potential for differential clinical activity M Hafner, CE Mills, K Subramanian, C Chen, M Chung, SA Boswell, ... Cell chemical biology 26 (8), 1067-1080. e8, 2019 | 171 | 2019 |
| A multi-center study on the reproducibility of drug-response assays in mammalian cell lines M Niepel, M Hafner, CE Mills, K Subramanian, EH Williams, M Chung, ... Cell systems 9 (1), 35-48. e5, 2019 | 122 | 2019 |
| Development of a selective CDK7 covalent inhibitor reveals predominant cell-cycle phenotype CM Olson, Y Liang, A Leggett, WD Park, L Li, CE Mills, SZ Elsarrag, ... Cell chemical biology 26 (6), 792-803. e10, 2019 | 119 | 2019 |
| The kinase chemogenomic set (KCGS): an open science resource for kinase vulnerability identification CI Wells, H Al-Ali, DM Andrews, CRM Asquith, AD Axtman, I Dikic, ... International journal of molecular sciences 22 (2), 566, 2021 | 78 | 2021 |
| Development and characterization of a Wee1 kinase degrader Z Li, BJ Pinch, CM Olson, KA Donovan, RP Nowak, CE Mills, DA Scott, ... Cell chemical biology 27 (1), 57-65. e9, 2020 | 75 | 2020 |
| Development of CDK2 and CDK5 dual degrader TMX‐2172 M Teng, J Jiang, Z He, NP Kwiatkowski, KA Donovan, CE Mills, C Victor, ... Angewandte Chemie 132 (33), 13969-13974, 2020 | 51 | 2020 |
| Human health and the biological effects of tritium in drinking water: prudent policy through science–addressing the ODWAC new recommendation S Dingwall, CE Mills, N Phan, K Taylor, DR Boreham Dose-Response 9 (1), dose-response. 10-048. Boreham, 2011 | 38 | 2011 |
| Targeting TBK1 to overcome resistance to cancer immunotherapy Y Sun, O Revach, S Anderson, EA Kessler, CH Wolfe, A Jenney, CE Mills, ... Nature 615 (7950), 158-167, 2023 | 36 | 2023 |
| Temporal and spatial topography of cell proliferation in cancer G Gaglia, S Kabraji, D Rammos, Y Dai, A Verma, S Wang, CE Mills, ... Nature cell biology 24 (3), 316-326, 2022 | 35 | 2022 |
| Torin2 exploits replication and checkpoint vulnerabilities to cause death of PI3K-activated triple-negative breast cancer cells SS Chopra, A Jenney, A Palmer, M Niepel, M Chung, C Mills, ... Cell systems 10 (1), 66-81. e11, 2020 | 29 | 2020 |
| Inhibition of haspin kinase promotes cell-intrinsic and extrinsic antitumor activity JC Melms, S Vallabhaneni, CE Mills, C Yapp, JY Chen, E Morelli, ... Cancer research 80 (4), 798-810, 2020 | 25 | 2020 |
| Integrating multi-omics data reveals function and therapeutic potential of deubiquitinating enzymes LM Doherty, CE Mills, SA Boswell, X Liu, CT Hoyt, B Gyori, SJ Buhrlage, ... Elife 11, e72879, 2022 | 22 | 2022 |
| Chemical biology toolkit for DCLK1 reveals connection to RNA processing Y Liu, FM Ferguson, L Li, M Kuljanin, CE Mills, K Subramanian, ... Cell chemical biology 27 (10), 1229-1240. e4, 2020 | 21 | 2020 |
| Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells A Färkkilä, A Rodríguez, J Oikkonen, DC Gulhan, H Nguyen, ... Cancer research 81 (10), 2774-2787, 2021 | 20 | 2021 |
| A cloverleaf detector system for in vivo bone lead measurement DEB Fleming, CE Mills Medical physics 34 (3), 945-951, 2007 | 19 | 2007 |
| The relative biological effectiveness of low-dose mammography quality X rays in the human breast MCF-10A cell line CE Mills, C Thome, D Koff, DW Andrews, DR Boreham Radiation Research 183 (1), 42-51, 2015 | 14 | 2015 |
| A multi-omic analysis of MCF10A cells provides a resource for integrative assessment of ligand-mediated molecular and phenotypic responses SM Gross, MA Dane, RL Smith, KL Devlin, IC McLean, DS Derrick, ... Communications biology 5 (1), 1066, 2022 | 13 | 2022 |
| A mouse-human phase I co-clinical trial of taselisib in combination with TDM1 in advanced HER2-positive breast cancer (MBC). O Metzger Filho, S Goel, WT Barry, EP Hamilton, SM Tolaney, DA Yardley, ... Journal of Clinical Oncology 35 (15_suppl), 1030-1030, 2017 | 12 | 2017 |
Peter K. SorgerHarvard Medical SchoolDirección de correo verificada de hms.harvard.edu
